RNS & Investor News

2021

Contract signed with multinational consumer goods company

02 June 2015

OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces that it has entered into an option agreement with a multinational consumer goods company in relation to its cholesterol reducing product. The terms of the agreement provide the multinational (for a nominal payment) with an option to enter into a definitive agreement following the results of a trial.

The terms of the agreement are confidential and no further details can be disclosed. A further announcement will be made in due course.

Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce the signing of our first agreement with a global partner for our cholesterol reducing product. We believe that OptiBiotix's strong science base together with our partners brand portfolio and global reach will help both companies improve the health and well being of people around the world."

 

For further information, please contact:

OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
www.optibiotix.com
Contact via Walbrook below
Cairn Financial Advisers LLP
Liam Murray / Avi Robinson
Tel: 020 7148 7900
Hybridan LLP
Claire Louise Noyce
Tel: 020 3713 4581
Peterhouse Corporate Finance Ltd
Lucy Williams / Duncan Vasey
Tel: 020 7469 0936
Walbrook PR Ltd
Anna Dunphy
Mike Wort
Tel: 020 7933 8780 or [email protected]
Mob: 07876 741 001
Mob: 07900 608 002

 

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

 

2020

Contract signed with multinational consumer goods company

02 June 2015

OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces that it has entered into an option agreement with a multinational consumer goods company in relation to its cholesterol reducing product. The terms of the agreement provide the multinational (for a nominal payment) with an option to enter into a definitive agreement following the results of a trial.

The terms of the agreement are confidential and no further details can be disclosed. A further announcement will be made in due course.

Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce the signing of our first agreement with a global partner for our cholesterol reducing product. We believe that OptiBiotix's strong science base together with our partners brand portfolio and global reach will help both companies improve the health and well being of people around the world."

 

For further information, please contact:

OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
www.optibiotix.com
Contact via Walbrook below
Cairn Financial Advisers LLP
Liam Murray / Avi Robinson
Tel: 020 7148 7900
Hybridan LLP
Claire Louise Noyce
Tel: 020 3713 4581
Peterhouse Corporate Finance Ltd
Lucy Williams / Duncan Vasey
Tel: 020 7469 0936
Walbrook PR Ltd
Anna Dunphy
Mike Wort
Tel: 020 7933 8780 or [email protected]
Mob: 07876 741 001
Mob: 07900 608 002

 

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

 

2019

Contract signed with multinational consumer goods company

02 June 2015

OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces that it has entered into an option agreement with a multinational consumer goods company in relation to its cholesterol reducing product. The terms of the agreement provide the multinational (for a nominal payment) with an option to enter into a definitive agreement following the results of a trial.

The terms of the agreement are confidential and no further details can be disclosed. A further announcement will be made in due course.

Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce the signing of our first agreement with a global partner for our cholesterol reducing product. We believe that OptiBiotix's strong science base together with our partners brand portfolio and global reach will help both companies improve the health and well being of people around the world."

 

For further information, please contact:

OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
www.optibiotix.com
Contact via Walbrook below
Cairn Financial Advisers LLP
Liam Murray / Avi Robinson
Tel: 020 7148 7900
Hybridan LLP
Claire Louise Noyce
Tel: 020 3713 4581
Peterhouse Corporate Finance Ltd
Lucy Williams / Duncan Vasey
Tel: 020 7469 0936
Walbrook PR Ltd
Anna Dunphy
Mike Wort
Tel: 020 7933 8780 or [email protected]
Mob: 07876 741 001
Mob: 07900 608 002

 

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

 

2018

Contract signed with multinational consumer goods company

02 June 2015

OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces that it has entered into an option agreement with a multinational consumer goods company in relation to its cholesterol reducing product. The terms of the agreement provide the multinational (for a nominal payment) with an option to enter into a definitive agreement following the results of a trial.

The terms of the agreement are confidential and no further details can be disclosed. A further announcement will be made in due course.

Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce the signing of our first agreement with a global partner for our cholesterol reducing product. We believe that OptiBiotix's strong science base together with our partners brand portfolio and global reach will help both companies improve the health and well being of people around the world."

 

For further information, please contact:

OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
www.optibiotix.com
Contact via Walbrook below
Cairn Financial Advisers LLP
Liam Murray / Avi Robinson
Tel: 020 7148 7900
Hybridan LLP
Claire Louise Noyce
Tel: 020 3713 4581
Peterhouse Corporate Finance Ltd
Lucy Williams / Duncan Vasey
Tel: 020 7469 0936
Walbrook PR Ltd
Anna Dunphy
Mike Wort
Tel: 020 7933 8780 or [email protected]
Mob: 07876 741 001
Mob: 07900 608 002

 

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

 

2017

Contract signed with multinational consumer goods company

02 June 2015

OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces that it has entered into an option agreement with a multinational consumer goods company in relation to its cholesterol reducing product. The terms of the agreement provide the multinational (for a nominal payment) with an option to enter into a definitive agreement following the results of a trial.

The terms of the agreement are confidential and no further details can be disclosed. A further announcement will be made in due course.

Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce the signing of our first agreement with a global partner for our cholesterol reducing product. We believe that OptiBiotix's strong science base together with our partners brand portfolio and global reach will help both companies improve the health and well being of people around the world."

 

For further information, please contact:

OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
www.optibiotix.com
Contact via Walbrook below
Cairn Financial Advisers LLP
Liam Murray / Avi Robinson
Tel: 020 7148 7900
Hybridan LLP
Claire Louise Noyce
Tel: 020 3713 4581
Peterhouse Corporate Finance Ltd
Lucy Williams / Duncan Vasey
Tel: 020 7469 0936
Walbrook PR Ltd
Anna Dunphy
Mike Wort
Tel: 020 7933 8780 or [email protected]
Mob: 07876 741 001
Mob: 07900 608 002

 

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

 

2016

Contract signed with multinational consumer goods company

02 June 2015

OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces that it has entered into an option agreement with a multinational consumer goods company in relation to its cholesterol reducing product. The terms of the agreement provide the multinational (for a nominal payment) with an option to enter into a definitive agreement following the results of a trial.

The terms of the agreement are confidential and no further details can be disclosed. A further announcement will be made in due course.

Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce the signing of our first agreement with a global partner for our cholesterol reducing product. We believe that OptiBiotix's strong science base together with our partners brand portfolio and global reach will help both companies improve the health and well being of people around the world."

 

For further information, please contact:

OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
www.optibiotix.com
Contact via Walbrook below
Cairn Financial Advisers LLP
Liam Murray / Avi Robinson
Tel: 020 7148 7900
Hybridan LLP
Claire Louise Noyce
Tel: 020 3713 4581
Peterhouse Corporate Finance Ltd
Lucy Williams / Duncan Vasey
Tel: 020 7469 0936
Walbrook PR Ltd
Anna Dunphy
Mike Wort
Tel: 020 7933 8780 or [email protected]
Mob: 07876 741 001
Mob: 07900 608 002

 

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

 

2015

Contract signed with multinational consumer goods company

02 June 2015

OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces that it has entered into an option agreement with a multinational consumer goods company in relation to its cholesterol reducing product. The terms of the agreement provide the multinational (for a nominal payment) with an option to enter into a definitive agreement following the results of a trial.

The terms of the agreement are confidential and no further details can be disclosed. A further announcement will be made in due course.

Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce the signing of our first agreement with a global partner for our cholesterol reducing product. We believe that OptiBiotix's strong science base together with our partners brand portfolio and global reach will help both companies improve the health and well being of people around the world."

 

For further information, please contact:

OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
www.optibiotix.com
Contact via Walbrook below
Cairn Financial Advisers LLP
Liam Murray / Avi Robinson
Tel: 020 7148 7900
Hybridan LLP
Claire Louise Noyce
Tel: 020 3713 4581
Peterhouse Corporate Finance Ltd
Lucy Williams / Duncan Vasey
Tel: 020 7469 0936
Walbrook PR Ltd
Anna Dunphy
Mike Wort
Tel: 020 7933 8780 or [email protected]
Mob: 07876 741 001
Mob: 07900 608 002

 

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

 

2014

Contract signed with multinational consumer goods company

02 June 2015

OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces that it has entered into an option agreement with a multinational consumer goods company in relation to its cholesterol reducing product. The terms of the agreement provide the multinational (for a nominal payment) with an option to enter into a definitive agreement following the results of a trial.

The terms of the agreement are confidential and no further details can be disclosed. A further announcement will be made in due course.

Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce the signing of our first agreement with a global partner for our cholesterol reducing product. We believe that OptiBiotix's strong science base together with our partners brand portfolio and global reach will help both companies improve the health and well being of people around the world."

 

For further information, please contact:

OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
www.optibiotix.com
Contact via Walbrook below
Cairn Financial Advisers LLP
Liam Murray / Avi Robinson
Tel: 020 7148 7900
Hybridan LLP
Claire Louise Noyce
Tel: 020 3713 4581
Peterhouse Corporate Finance Ltd
Lucy Williams / Duncan Vasey
Tel: 020 7469 0936
Walbrook PR Ltd
Anna Dunphy
Mike Wort
Tel: 020 7933 8780 or [email protected]
Mob: 07876 741 001
Mob: 07900 608 002

 

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

 

2013

Contract signed with multinational consumer goods company

02 June 2015

OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces that it has entered into an option agreement with a multinational consumer goods company in relation to its cholesterol reducing product. The terms of the agreement provide the multinational (for a nominal payment) with an option to enter into a definitive agreement following the results of a trial.

The terms of the agreement are confidential and no further details can be disclosed. A further announcement will be made in due course.

Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce the signing of our first agreement with a global partner for our cholesterol reducing product. We believe that OptiBiotix's strong science base together with our partners brand portfolio and global reach will help both companies improve the health and well being of people around the world."

 

For further information, please contact:

OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
www.optibiotix.com
Contact via Walbrook below
Cairn Financial Advisers LLP
Liam Murray / Avi Robinson
Tel: 020 7148 7900
Hybridan LLP
Claire Louise Noyce
Tel: 020 3713 4581
Peterhouse Corporate Finance Ltd
Lucy Williams / Duncan Vasey
Tel: 020 7469 0936
Walbrook PR Ltd
Anna Dunphy
Mike Wort
Tel: 020 7933 8780 or [email protected]
Mob: 07876 741 001
Mob: 07900 608 002

 

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.